ISO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IsoPlexis's EBITDA per Share for the three months ended in Dec. 2022 was $-0.77. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.44.
During the past 3 years, the average EBITDA per Share Growth Rate was -93.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.
The historical rank and industry rank for IsoPlexis's EBITDA per Share or its related term are showing as below:
During the past 4 years, the highest 3-Year average EBITDA per Share Growth Rate of IsoPlexis was -93.10% per year. The lowest was -93.10% per year. And the median was -93.10% per year.
IsoPlexis's EBITDA for the three months ended in Dec. 2022 was $-30.47 Mil.
During the past 3 years, the average EBITDA Growth Rate was -93.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 4 years, the highest 3-Year average EBITDA Growth Rate of IsoPlexis was -93.90% per year. The lowest was -93.90% per year. And the median was -93.90% per year.
The historical data trend for IsoPlexis's EBITDA per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
EBITDA per Share | -0.34 | -10.43 | -7.39 | -2.43 |
IsoPlexis Quarterly Data | |||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
EBITDA per Share | Get a 7-Day Free Trial | -0.60 | -0.68 | -0.59 | -0.40 | -0.77 |
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IsoPlexis's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as
EBITDA per Share | (A: Dec. 2022 ) | ||
= | EBITDA | / | Shares Outstanding (Diluted Average) | = | -95.696 | / | 39.318 |
= | -2.43 |
IsoPlexis's EBITDA per Share for the quarter that ended in Dec. 2022 is calculated as
EBITDA per Share | (Q: Dec. 2022 ) | ||
= | EBITDA | / | Shares Outstanding (Diluted Average) | = | -30.474 | / | 39.590 |
= | -0.77 |
EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis (NAS:ISO) EBITDA per Share Explanation
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventoryEBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.
Thank you for viewing the detailed overview of IsoPlexis's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nachum Shamir | director | 12212 TECHNOLOGY BLVD, AUSTIN TX 78727 |
John Strahley | officer: Chief Financial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Sean Mackay | director, officer: Chief Executive Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rew Richard W. Ii | officer: SVP, GC & Secretary | 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735 |
James R Heath | director | C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405 |
Michael Egholm | director | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
Siddhartha Kadia | director | 7475 LUSK BOULEVARD, SAN DIEGO CA 92121 |
Jason W. Myers | director | C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301 |
John G. Conley | director | 396 GREAT MEADOWS RD, CONCORD MA 01742-1803 |
Gregory P. Ho | director, 10 percent owner | C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
Peter Siesel | officer: Chief Commercial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Jing Zhou | officer: Chief Scientific Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rajesh T. Khakhar | officer: VP, Finance | 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405 |
Northpond Capital Gp, Llc | 10 percent owner | 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By PRNewswire PRNewswire • 02-03-2023
By GuruFocusNews GuruFocusNews • 02-16-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
By PRNewswire PRNewswire • 03-02-2023
By PurpleRose PurpleRose • 07-21-2022
By Value_Insider Value_Insider • 10-19-2022
By GuruFocusNews GuruFocusNews • 02-11-2022
By Stock market mentor Stock market mentor • 01-12-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.